Hospira Tells Jury Biosimilar Was Covered By Safe Harbor
Pharmaceutical company Hospira Inc. told a freshly empaneled Delaware federal jury Monday that its production of a biosimilar version of an Amgen Inc. biologic anemia treatment doesn't infringe Amgen's patents because...To view the full article, register now.
Already a subscriber? Click here to view full article